Protagenic TherapeuticsPTIX
13F holders, Q3 2024 (September 30)11holders
2new positions
2sold out
1famous investor
$0.63avg. 13F price*
At the end of Q3 2024, 11 institutions reported holding Protagenic Therapeutics Inc. (PTIX) in their 13F filings, unchanged from Q2 2024. 2 opened new positions and 2 sold out. The largest holders were Citadel Advisors ($26K), Vanguard Group Inc. ($21K) and Geode Capital Management, LLC ($17K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Protagenic Therapeutics Inc.
- CUSIP
- 74365N202
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $34K |
| Exits | 2 | $41K |
All 13F filers, Q2 2024 → Q3 2024: 54,062 shares bought and 48,762 shares sold, net +5,300 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Citadel Advisors | 0.00% | New | 40,909 | $26K |
| Vanguard Group Inc. | 0.00% | No change | 33,166 | $21K |
| Geode Capital Management, LLC | 0.00% | Reduce -10.6% | 26,054 | $17K |
| Osaic Holdings, Inc. | 0.00% | No change | 21,414 | $13K |
| State Street Corp. | 0.00% | No change | 13,812 | $9K |
| Virtu Financial LLC | 0.00% | New | 13,118 | $8K |
| UBS Group AG | 0.00% | Reduce -3.4% | 9,740 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.3% | 6,829 | $4K |
| Bank of America Corp. | 0.00% | Add +41.4% | 41 | $26 |
| Morgan Stanley | 0.00% | No change | 1 | $1 |
| Cwm, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PTIX's weight in each manager's 13F, not the share of Protagenic Therapeutics Inc. the manager owns.